Big pharma turns to AI to speed drug discovery, GSK signs deal

Big pharma turns to AI to speed drug discovery, GSK signs deal


The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline as part of a new $US43 million deal. Other pharmaceutical giants, including Merck & Co, Johnson & Johnson and Sanofi, are also exploring the potential of artificial intelligence to help streamline the drug discovery process.



from Biotech News